- Home
- FONR vs QNCX Comparison
FONR vs QNCX Comparison
Compare FONR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- QNCX
- Stock Information
- Founded
- FONR 1978
- QNCX 2012
- Country
- FONR United States
- QNCX United States
- Employees
- FONR N/A
- QNCX N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FONR Health Care
- QNCX Health Care
- Exchange
- FONR Nasdaq
- QNCX Nasdaq
- Market Cap
- FONR 100.6M
- QNCX 85.9M
- IPO Year
- FONR 1987
- QNCX 2019
- Fundamental
- Price
- FONR $15.30
- QNCX $1.61
- Analyst Decision
- FONR
- QNCX Strong Buy
- Analyst Count
- FONR 0
- QNCX 6
- Target Price
- FONR N/A
- QNCX $8.00
- AVG Volume (30 Days)
- FONR 9.9K
- QNCX 137.7K
- Earning Date
- FONR 09-12-2025
- QNCX 11-12-2025
- Dividend Yield
- FONR N/A
- QNCX N/A
- EPS Growth
- FONR N/A
- QNCX N/A
- EPS
- FONR 1.21
- QNCX N/A
- Revenue
- FONR $104,351,318.00
- QNCX N/A
- Revenue This Year
- FONR N/A
- QNCX N/A
- Revenue Next Year
- FONR N/A
- QNCX N/A
- P/E Ratio
- FONR $12.77
- QNCX N/A
- Revenue Growth
- FONR 1.43
- QNCX N/A
- 52 Week Low
- FONR $12.00
- QNCX $0.69
- 52 Week High
- FONR $17.98
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- FONR 43.73
- QNCX 49.14
- Support Level
- FONR $15.19
- QNCX $1.56
- Resistance Level
- FONR $15.79
- QNCX $1.67
- Average True Range (ATR)
- FONR 0.26
- QNCX 0.07
- MACD
- FONR -0.03
- QNCX 0.00
- Stochastic Oscillator
- FONR 18.99
- QNCX 69.70
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.